Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement: Results From the Multicenter International BASILICA Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Jaffar M, Babaliaros Vasilis C, Greenbaum Adam B, Spies Christian, Daniels David, Depta Jeremiah P, Oldemeyer J Bradley, Whisenant Brian, McCabe James M, Muhammad Kamran I, George Isaac, Mahoney Paul, Lanz Jonas, Laham Roger J, Shah Pinak B, Chhatriwalla Adnan, Yazdani Shahram, Hanzel George, Pershad Ashish, Leonardi Robert A, Khalil Ramzi, Tang Gilbert H L, Herrmann Howard C, Agarwal Shikhar, Fail Peter S, Zhang Ming, Pop Andrei, Lisko John, Perdoncin Emily, Koch Rachel L, Ben-Dor Itsik, Satler Lowell F, Zhang Cheng, Cohen Jeffrey E, Lederman Robert J, Waksman Ron, Rogers Toby
Аннотация
BACKGROUND: Transcatheter aortic valve replacement causes coronary artery obstruction in 0.7% of cases, with 40% to 50% mortality. BASILICA is a procedure to prevent coronary obstruction. Safety and feasibility in a large patient cohort is lacking.
METHODS: The international BASILICA registry was a retrospective, multicenter, real-world registry of patients at risk of coronary artery obstruction undergoing BASILICA and transcatheter aortic valve replacement. Valve Academic Research Consortium-2 definitions were used to adjudicate events.
RESULTS: Between June 2017 and December 2020, 214 patients were included from 25 centers in North America and Europe; 72.8% had bioprosthetic aortic valves and 78.5% underwent solo BASILICA. Leaflet traversal was successful in 94.9% and leaflet laceration in 94.4%. Partial or complete coronary artery obstruction was seen in 4.7%. Procedure success, defined as successful BASILICA traversal and laceration without mortality, coronary obstruction, or emergency intervention, was achieved in 86.9%. Thirty-day mortality was 2.8% and stroke was 2.8%, with 0.5% disabling stroke. Thirty-day death and disabling stroke were seen in 3.4%. Valve Academic Research Consortium-2 composite safety was achieved in 82.8%. One-year survival was 83.9%. Outcomes were similar between solo and doppio BASILICA, between native and bioprosthetic valves, and with the use of cerebral embolic protection.
CONCLUSIONS: BASILICA is safe, with low reported rates of stroke and death. BASILICA is feasible in the real-world setting, with a high procedure success rate and low rates of coronary artery obstruction.